





UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20201 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/758,036	01/11/2001	Ekkehard Leberer	38005-0126	8288	
75	90 01/29/2002			_	
Patricia D. Granados Heller Ehrman White & McAuliffe LLP Suite 300 1666 K Street, N.W. Washington, DC 20006			EXAMINER		
			SANDALS, WILLIAM O		
			ART UNIT	PAPER NUMBER	
,, admington, D			1636		
			DATE MAIL ED: 01/20/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. 09/758,036

Applicant(s)

Leberer et al.

Office Action Summary

Examiner

William Sandals

Art Unit 1636

	The MAILING DATE of this c mmunication appears	on the cover sheet w	with the corresp	o ndence address		
A SHOTHE No External after the between the control of the contr	For Reply ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION. Insigns of time may be available under the provisions of 37 Ceter SIX (6) MONTHS from the mailing date of this communication period for reply specified above is less than thirty (30) days a considered timely. In period for reply is specified above, the maximum statutory immunication. The to reply within the set or extended period for reply will, by the property received by the Office later than three months after the	CFR 1.136 (a). In no excation. s, a reply within the staper period will apply and ways that are the apply to	vent, however, natutory minimum will expire SIX (6	may a reply be timely filed of thirty (30) days will b) MONTHS from the mailing date of this ome ABANDONED (35 U.S.C. § 133).		
ea	rned patent term adjustment. See 37 CFR 1.704(b).	a maining date of this c	,onlination, e	sven in timely med, may reduce any		
Status 1) 💢	Responsive to communication(s) filed on Jan 11, 2	2001		·		
2a) 🗌		tion is non-final.				
3) 🗆	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
Disposi	tion of Claims					
4) 💢	Claim(s) <u>1-24</u>		is/are	pending in the application.		
4	a) Of the above, claim(s)		is/are	e withdrawn from consideration.		
5) 🗌	Claim(s)		· · · · · · · · · · · · · · · · · · ·	is/are allowed.		
6) 🗆	Claim(s)			is/are rejected.		
7) 🗆	Claim(s)			is/are objected to.		
8) 💢	Claims <u>1-24</u>	are sub	bject to restric	tion and/or election requirement.		
Applica	tion Papers					
9) 🗆	The specification is objected to by the Examiner.					
10)	The drawing(s) filed on is/are objected to by the Examiner.					
11)	The proposed drawing correction filed on is: a) _ approved b) _ disapproved.					
12)	The oath or declaration is objected to by the Exam	iiner.				
13)□ a)□	under 35 U.S.C. § 119 Acknowledgement is made of a claim for foreign p All b)□ Some* c)□ None of: 1.□ Certified copies of the priority documents have		S.C. § 119(a)-	-(d).		
	 Certified copies of the priority documents have 		Δnnlication N	lo.		
;	3. Copies of the certified copies of the priority d application from the International Bure ee the attached detailed Office action for a list of th	documents have be eau (PCT Rule 17.2	en received in			
14)	Acknowledgement is made of a claim for domestic	priority under 35 t	U.S.C. § 119(e).		
Attachm	ent(s)					
15) 🔲 No	otice of References Cited (PTO-892)	18) Interview Summa	ry (PTO-413) Paper	No(s)		
16) 🗌 No	otice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informa				
17) 🔲 Int	7) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 20) Other:					

Rilas Att 40

Page 2

Application/Control Number: 09/758,036

Art Unit: 1636

DETAILED ACTION

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-10, 19, 20 and 21, drawn to a process for identifying activators or inhibitors of a eukaryotic potassium channel, classified in class 435, subclass 4.
 - II. Claims 11, 12 14-17 and 22, drawn to a mutated S. cerevisiae cell with endogenous potassium channels which are not expressed, classified in class 435, subclass 245.
 - III. Claim 13, drawn to a S. cerevisiae cell DSM 13197, classified in class 435, subclass 255.2.
 - IV. Claim 18, drawn to a process of making a potassium channel S. cerevisiae knockout, classified in class 435, subclass 270.
 - V. Claim 23 and 24, drawn to a process for preparation of a medicament containing an activator or inhibitor identified by the method of Group I, classified in class 424, subclass 400.
- 2. The inventions are distinct, each from the other because of the following reasons:

 Inventions of each of Groups I, IV and V are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct from each other if they are shown to be separately usable. In the instant case, invention of Group I has separate utility such

Application/Control Number: 09/758,036 Page 3

Art Unit: 1636

as identifying a compound which inhibits or activates a potassium channel. The invention of Group IV has a separate utility such as making a knock out cell by recombinant means. The invention of Group V has a separate utility such as a process of making a medicament. See MPEP § 806.05(d).

- 3. Inventions of Groups I and II & III are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the subcombination as claimed because the method of Group I may be performed without the mutant S. cerevisiae cells of Groups II and III. The subcombination has separate utility such as the S. cerevisiae cells may be used to produce a recombinantly expressed product.
- 4. Inventions of Group IV and II or III are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the cells may be made by a different process such as culturing and selection of natural mutants.
- 5. Inventions of Group II or III and V are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct from each other if they are

Application/Control Number: 09/758,036 Page 4

Art Unit: 1636

shown to be separately usable. In the instant case, invention of Group II or III have separate utility such as the cells can be used in methods of recombinantly expressing a product. See MPEP § 806.05(d).

- 6. Inventions of Group II and III are related as mutually exclusive species in an intermediate-final product relationship. Distinctness is proven for claims in this relationship if the intermediate product is useful to make other than the final product (MPEP § 806.04(b), 3rd paragraph), and the species are patentably distinct (MPEP § 806.04(h)). In the instant case, the intermediate product is deemed to be useful to make mutant S. cerevisiae cells other than DSM 13197 and the inventions are deemed patentably distinct since there is nothing on this record to show them to be obvious variants. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions anticipated by the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
- 7. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Application/Control Number: 09/758,036 Page 5

Art Unit: 1636

8. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

9. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

10. Certain papers related to this application are *welcomed* to be submitted to Art Unit 1636 by facsimile transmission. The FAX numbers are (703) 308-4242 and 305-3014. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 CFR 1.6(d)). NOTE: If applicant *does* submit a paper by FAX, the original copy should be retained by the applicant or applicant's representative, and the FAX receipt from your FAX machine is proof of delivery. NO DUPLICATE COPIES SHOULD BE SUBMITTED, so as to avoid the processing of duplicate papers in the Office.

Application/Control Number: 09/758,036

Page 6

Art Unit: 1636

Any inquiry concerning this communication or earlier communications should be directed

to Dr. William Sandals whose telephone number is (703) 305-1982. The examiner normally can

be reached Monday through Friday from 8:30 AM to 5:00 PM, EST. If attempts to reach the

examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel can be reached

at (703) 305-1998.

Any inquiry of a general nature or relating to the status of this application should be

directed to the Zeta Adams, whose telephone number is (703) 305-3291.

William Sandals, Ph.D.

all AND

Examiner

January 24, 2002